Saturday, April 28, 2018
Intercontinental
New York, NY Times Square
300 W 44th St, New York, NY 10036
(212) 803-4500

In 2018, groundbreaking research continues to revolutionize treatment approaches and modalities across oncology disciplines. Within the diverse specialties of medical oncology, surgical oncology, and radiation oncology, a conference for clinicians who manage some of the most difficult-to-treat forms of gastrointestinal (GI) cancers is of particular value. The School of Gastrointestinal Oncology™ (SOGO^®), a program focused exclusively on these tumors, takes the latest advances in research, and provides an educational venue that facilitates the practical application of new evidence to improve outcomes in your patients. This intensive 1-day, multi-track, curriculum-based, conference demonstrates how the latest data can be seamlessly incorporated into contemporary practice settings where patients with GI cancers receive care.

SOGO^® prides itself on its multidisciplinary focus, featuring multiple break out tracks dedicated to medical oncology, surgical, oncology, and radiation oncology, as well as a nursing track. Attendees are brought together repeatedly throughout the day, allowing for a shared learning experience in sessions that aim to address your most difficult clinical scenarios. Now in its third year, our expert faculty will integrate the latest data on prognostic and predictive markers and how these data impact clinical decision-making on evolving treatment strategies into a case-based format. Our goal is your goal, to optimize outcomes for each one of your patients with GI cancers. See you in New York!

• How disease pathology and actionable biomarkers inform clinical decision-making
• Advances in surgery including new frontiers in minimally invasive techniques
• The expanding role that molecularly targeted and immunotherapeutic approaches are playing in GI cancers treatment
• Optimized sequencing strategies to personalize care for your patients
• Contemporary use of multidisciplinary approaches to optimize patient outcomes in advanced forms of GI cancers

• Describe the patient and tumor-related prognostic markers important to the stratification of risk and clinical decision-making in managing patients with GI malignancies
• Use pivotal trial evidence to inform multidisciplinary clinical decision-making in the personalized management of advanced forms of GI cancers
• Assess strategies to proactively plan for, prevent, and mitigate predictable toxicities associated with therapies used to treat GI tumors
• Apply emerging clinical trial data to manage cases in the context of evolving treatment paradigms for GI cancers

This activity is supported by educational grants from Boston Biomedical, Inc., Eisai, Exelixis, Inc., Lilly, Merck Sharp & Dohme Corp., and Taiho Oncology, Inc.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Physicians' Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource^®, LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 6.75 Nursing Contact Hours.

This educational program is directed toward oncologists and gastroenterologists whose primary practice focus is gastrointestinal (GI) cancers, and who intend to reinforce their knowledge base and expand their expertise in GI diagnosis, risk stratification, personalization of care, and best practices for multidisciplinary communication. Participants will be primarily oncologists, gastroenterologists, or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of GI cancers.